摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(4-hydroxypiperidin-1-yl)-2-methylpropan-1-one | 1082928-57-1

中文名称
——
中文别名
——
英文名称
1-(4-hydroxypiperidin-1-yl)-2-methylpropan-1-one
英文别名
——
1-(4-hydroxypiperidin-1-yl)-2-methylpropan-1-one化学式
CAS
1082928-57-1
化学式
C9H17NO2
mdl
MFCD11044213
分子量
171.239
InChiKey
AAUZTEFUHQJOJK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.6
  • 重原子数:
    12
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.888
  • 拓扑面积:
    40.5
  • 氢给体数:
    1
  • 氢受体数:
    2

反应信息

点击查看最新优质反应信息

文献信息

  • COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASE 4 POLYPEPTIDES
    申请人:Arvinas, Inc.
    公开号:US20190151295A1
    公开(公告)日:2019-05-23
    The present disclosure relates to bifunctional compounds, which find utility as modulators of Interleukin-1 Receptor-Associated Kinase 4 (IRAK-4); the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hppel-Lindau, cereblon, ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.
    本公开涉及双功能化合物,其作为白细胞介素-1受体相关激酶4(IRAK-4;目标蛋白)的调节剂具有实用性。具体而言,本公开涉及包含一端结合E3泛素连接酶的Von Hppel-Lindau、cereblon配体的双功能化合物,另一端结合目标蛋白的部分,使得目标蛋白靠近泛素连接酶以实现目标蛋白的降解(和抑制)。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由目标蛋白聚集或积累导致的疾病或紊乱。
  • [EN] AMIDE DERIVATIVES AS SIRTUIN MODULATORS<br/>[FR] DÉRIVÉS D'AMIDE COMME MODULATEURS DE SIRTUINES
    申请人:SIRTRIS PHARMACEUTICALS INC
    公开号:WO2009058348A1
    公开(公告)日:2009-05-07
    Provided herein are novel sirtuin-modulating compounds represented by Structural Formula (I) and methods of use thereof. The sirtuin-modulating compounds may be used for increasing the lifespan of a cell, and treating and/or preventing a wide variety of diseases and disorders including, for example, diseases or disorders related to aging or stress, diabetes, obesity, neurodegenerative diseases, cardiovascular disease, blood clotting disorders, inflammation, cancer, and/or flushing as well as diseases or disorders that would benfit from increased mitochondrial activity. Also provided are compositions comprising a sirtuin- modulating compound in combination with another therapeutic agent.
    提供的是由结构公式(I)表示的新的sirtuin调节化合物及其用途。sirtuin调节化合物可用于延长细胞寿命,以及治疗和/或预防多种疾病和紊乱,例如与衰老或压力、糖尿病、肥胖、神经退行性疾病、心血管疾病、凝血障碍、炎症、癌症和/或潮红相关的疾病或紊乱,以及将从增加线粒体活性中受益的疾病或紊乱。还提供了包含sirtuin调节化合物与另一种治疗剂的组合的药物组合物。
  • [EN] SWEET FLAVOR MODIFIER<br/>[FR] AGENT MODIFICATEUR DE LA SAVEUR SUCRÉE
    申请人:SENOMYX INC
    公开号:WO2013025560A1
    公开(公告)日:2013-02-21
    The present invention includes compounds having structural formula (I), or salts or solvates thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of compositions.
    本发明包括具有结构式(I)的化合物,或其盐或溶剂合物。这些化合物可用作甜味调味剂。本发明还包括包含本化合物的组合物以及增强组合物甜味的方法。
  • PYRIDO[3,2-d]PYRIMIDINE PI3K DELTA INHIBITOR COMPOUNDS AND METHODS OF USE
    申请人:Castanedo Georgette
    公开号:US20110207713A1
    公开(公告)日:2011-08-25
    Formula I compounds, including stereoisomers, geometric isomers, tautomers, metabolites and pharmaceutically acceptable salts thereof, are useful for inhibiting the delta isoform of PI3K, and for treating disorders mediated by lipid kinases such as inflammation, immunological disorders, and cancer. Methods of using compounds of Formula I for in vitro, in situ, and in vivo diagnosis, prevention or treatment of such disorders in mammalian cells, or associated pathological conditions, are disclosed.
    Formula I 化合物,包括立体异构体、几何异构体、互变异构体、代谢物及其药学上可接受的盐,对抑制 PI3K 的δ异构体以及治疗由脂质激酶介导的疾病,如炎症、免疫性疾病和癌症,具有用途。公开了利用 Formula I 化合物在哺乳动物细胞中进行体外、体内和体内诊断、预防或治疗此类疾病,或相关病理条件的方法。
  • Antifouling Compounds And Use Thereof
    申请人:Teo Lay Ming Serena
    公开号:US20110092518A1
    公开(公告)日:2011-04-21
    The present invention relates to the use of compounds which have the following general formula (I), wherein R 1 and R 2 are independently selected from optionally substituted aryl, optionally substituted C 1 to C 12 alkyl and H; and R 3 and R 4 are independently selected from hydroxy, optionally substituted C 1 to C 6 alkyl, optionally substituted phenyl and H, in a method of preventing or reducing fouling, particularly in the marine environment. The compounds of the present invention have the considerable advantage of providing the antifouling coating market with an organic alternative to the existing technology which relies heavily on the addition of copper to obtain significant antifouling effects. The compounds we have developed may be used as cheap, easy to prepare additives that do not contain metals and therefore have reduced toxicity in marine environment.
    本发明涉及使用具有以下一般式(I)的化合物,其中R1和R2分别选自可选取代芳基、可选取代的C1到C12烷基和H;R3和R4分别选自羟基、可选取代的C1到C6烷基、可选取代的苯基和H,在防止或减少污垢,特别是在海洋环境中的方法中。本发明的化合物具有显著优势,为防污涂层市场提供了一种有机替代现有技术的选择,现有技术主要依赖于添加铜来获得显著的防污效果。我们开发的化合物可作为廉价、易于制备的添加剂使用,不含金属,因此在海洋环境中具有较低的毒性。
查看更多